| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/27/2000 | WO2000042849A1 COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD |
| 07/27/2000 | WO2000025723A3 Methods and compositions for the prevention of tolerance to medications |
| 07/27/2000 | WO2000023592A3 Minimal promoters and uses thereof |
| 07/27/2000 | WO2000023086A3 Buffered compositions for dialysis |
| 07/27/2000 | WO2000001321A9 Methods and compositions for producing a cooling effect in tissues |
| 07/27/2000 | WO2000000221A9 Water soluble dry compositions |
| 07/27/2000 | WO1999066944A9 Methods for identifying novel multimeric agents that modulate receptors |
| 07/27/2000 | WO1999064033A9 Phosphodiesterase-v modulator drugs and their uses |
| 07/27/2000 | WO1999063994A9 MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE |
| 07/27/2000 | CA2360066A1 A pharmaceutical composition containing a compound having a phenolic hydroxyl group with coloring change being controlled |
| 07/27/2000 | CA2359709A1 Multiparticulate bisoprolol formulation |
| 07/27/2000 | CA2359633A1 Homing pro-apoptotic conjugates and methods of using same |
| 07/27/2000 | CA2359482A1 Organoprotective solutions |
| 07/27/2000 | CA2358584A1 Method of enhancing needleless transdermal powdered drug delivery |
| 07/27/2000 | CA2358524A1 Compositions and methods for mucosal delivery |
| 07/27/2000 | CA2358497A1 Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery |
| 07/27/2000 | CA2358474A1 Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt |
| 07/26/2000 | EP1022019A1 Suppository composition |
| 07/26/2000 | EP1022017A2 Cosmetic or pharmaceutical compositions for topical administration with improved stability |
| 07/26/2000 | EP1021464A1 Cellular receptor for hiv-1 vpr essential for g2/m phase transition of the cell cycle |
| 07/26/2000 | EP1021204A2 Bioadhesive compositions and methods for topical administration of active agents |
| 07/26/2000 | EP1021203A2 Delivery system |
| 07/26/2000 | EP1021202A1 Immunogenic peptides from the hpv e7 protein |
| 07/26/2000 | EP1021194A1 New improved formulation for treatment of osteoporosis |
| 07/26/2000 | EP1021192A1 Dexamethasone gel |
| 07/26/2000 | EP1021184A1 Use of flunarizine for the topical treatment of glaucoma |
| 07/26/2000 | EP1021171A1 Delayed total release gastrointestinal drug delivery system |
| 07/26/2000 | EP1021169A1 Active agent transport systems |
| 07/26/2000 | EP1021155A1 Water dispersible perfluoroether polymer encapsulates |
| 07/26/2000 | EP0930936B1 Method for preparing microcapsules of active substances coated with a polymer and novel microcapsules in particular resulting from the method |
| 07/26/2000 | EP0822808B1 Composite with sodium starch glycolate as a support material and products thereof |
| 07/26/2000 | EP0759775B1 Ifn-beta liquid formulations |
| 07/26/2000 | EP0755253B1 Intranasal antimigraine composition |
| 07/26/2000 | EP0643583B1 Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy |
| 07/26/2000 | CN1261363A Method of manufacturing sertindole |
| 07/26/2000 | CN1261287A Pharmaceutical formulations containing voriconazole |
| 07/26/2000 | CN1261280A Improved methods for processing activated protein C |
| 07/26/2000 | CN1261279A Pharmaceutical compositions containing eletriptan hemisulphate and caffeine |
| 07/26/2000 | CN1261273A Delayed-release dosage forms of sertraline |
| 07/26/2000 | CN1261271A Stable pharmaceutical administration forms of peptides, proteins and nucleic acids |
| 07/26/2000 | CN1261268A Shellac-containing cosmetic product |
| 07/26/2000 | CN1054855C Non-reducing oligosaccharide and its production and use |
| 07/26/2000 | CN1054744C Aqueous agent |
| 07/26/2000 | CN1054743C Argatroban consentrated aqueous solution |
| 07/25/2000 | US6093715 Process for producing riboflavin-containing granules |
| 07/25/2000 | US6093706 Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders |
| 07/25/2000 | US6093701 Method for covalent attachment of compounds to genes |
| 07/25/2000 | US6093699 Method for gene therapy involving suppression of an immune response |
| 07/25/2000 | US6093420 Sustained release matrix for high-dose insoluble drugs |
| 07/25/2000 | US6093399 Specific blood coagulation exemplified by in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody |
| 07/25/2000 | US6093394 Vaginal lactobacillus medicant |
| 07/25/2000 | US6093393 Methods for preparing and using clonogenic fibroblasts and transfected clonogenic fibroblasts |
| 07/25/2000 | US6093391 Peptide compositions containing polyoxyethylene-polyoxypropylene block copolymers that are useful in treatment of diseases and disorders with reduced side effects, ease in administering to desired target site, |
| 07/25/2000 | US6093385 For protecting the human skin or human hair from the sun's rays |
| 07/25/2000 | CA2010256C Protein anti-cancer agent |
| 07/20/2000 | WO2000042429A2 In vitro model for gastrointestinal inflammation |
| 07/20/2000 | WO2000042175A1 Methods for making proteins containing free cysteine residues |
| 07/20/2000 | WO2000042168A2 Bifidobacterium in the treatment of inflammatory disease |
| 07/20/2000 | WO2000042075A1 Malatyl polysaccharides, their production and their use |
| 07/20/2000 | WO2000042071A2 Compounds and methods to inhibit or augment an inflammatory response |
| 07/20/2000 | WO2000042050A1 Sulfated phosphatidylinositols, their preparation and use |
| 07/20/2000 | WO2000041740A2 Particles for oral delivery of peptides and proteins |
| 07/20/2000 | WO2000041732A1 Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
| 07/20/2000 | WO2000041730A1 A composition and method for the enhancement of the efficacy of drugs |
| 07/20/2000 | WO2000041727A1 Transcutaneous photodynamic treatment of targeted cells |
| 07/20/2000 | WO2000041725A2 Therapeutic compositions for metabolic bone disorders or bone metastases |
| 07/20/2000 | WO2000041707A2 USE OF $i(LACTOBACILLUS SALIVARIUS) |
| 07/20/2000 | WO2000041704A1 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| 07/20/2000 | WO2000041694A2 Compositions having improved stability |
| 07/20/2000 | WO2000041693A2 Compositions having improved delivery of actives |
| 07/20/2000 | WO2000041692A2 Compositions having improved stability |
| 07/20/2000 | WO2000041687A2 Composition and methods for administration of water-insoluble paclitaxel derivatives |
| 07/20/2000 | WO2000041683A2 Transdermal therapeutic system with self-adhesive matrix, containing organic acid addition salts of morphine- or morphinan-type alkaloids |
| 07/20/2000 | WO2000041682A1 Lipophilic microparticles containing a protein drug or antigen and formulation comprising same |
| 07/20/2000 | WO2000041681A2 MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST |
| 07/20/2000 | WO2000041680A1 Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| 07/20/2000 | WO2000041678A1 Methods for treating ovarian cancer, poly(phosphoester) compositions, and biodegradable articles for same |
| 07/20/2000 | WO2000041676A1 Spheronised self-emulsifying system for hydrophobic and water-sensitive agents |
| 07/20/2000 | WO2000041675A1 Cosmetics and skin preparations for external use |
| 07/20/2000 | WO2000041647A1 Sustained delivery of polyionic bioactive agents |
| 07/20/2000 | WO2000041576A1 Improved microbial preparations |
| 07/20/2000 | WO2000041548A2 Methods for glucagon suppression |
| 07/20/2000 | WO2000041546A2 Novel exendin agonist formulations and methods of administration thereof |
| 07/20/2000 | WO2000041528A2 Improved controlled release compositions and method |
| 07/20/2000 | WO2000041514A2 Conjugates of colony stimulating factors for targeting and imaging infection and inflammation |
| 07/20/2000 | WO2000041481A2 Medicament forms having controlled release and containing active substances which easily dissolve in water |
| 07/20/2000 | WO2000041474A2 Anti-cd3 immunotoxins and therapeutic uses therefor |
| 07/20/2000 | WO2000027437A3 Polymer grafting by polysaccharide synthases |
| 07/20/2000 | WO2000021521A3 Sertraline oral concentrate |
| 07/20/2000 | WO2000021510A3 Formulations of fexofenadine |
| 07/20/2000 | WO2000019990A3 Rar antagonists as male anti-fertility agents |
| 07/20/2000 | WO2000019985A3 New sustained release oral formulations |
| 07/20/2000 | WO2000019984A3 Coated medicament forms with controlled active substance release |
| 07/20/2000 | WO2000018949A3 Delivery of phosphoinositide polyphosphates into cells |
| 07/20/2000 | WO2000018370A3 Liquid pharmaceutical for oral delivery |
| 07/20/2000 | WO2000015203A3 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor |
| 07/20/2000 | WO2000010598B1 Recombinant botulinium toxin for the treatment of mucus hypersecretion |
| 07/20/2000 | WO2000002950A9 Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier |
| 07/20/2000 | WO2000000222A9 Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents |
| 07/20/2000 | WO1999064048A9 Inhibitors of hiv reverse transcriptase |